


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|---|--|
| In re Application of Sharon A. Baughman et al. Serial No.: To Be Assigned | Group Art Unit: To Be Assigned Examiner: To Be Assigned |
| Filed: June 20, 2003 For: Dosages for Treatment with Anti-ErbB2 Antibodies | <p align="center">Express Mail No. EV 351 923 988 US</p> <p align="center">June 20, 2003</p> <p align="center"></p> <p align="center">Wendy M. Lee</p> |

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR § 1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR § 1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

☐ **37 CFR § 1.97(c)**

- by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR § 1.113, or a notice of allowance under 37 CFR § 1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR § 1.17(p) **or** a statement as specified in 37 CFR § 1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) **and** a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR § 1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR § 1.704.

☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR § 1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/648,067, filed August 25, 2000 and relied upon in this application for an earlier filing date under 35 USC § 120.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-() " (nucleotide) and "BLAST Results B-1 - B-() " (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: June 20, 2003

By: _____

Wendy M. Lee

Reg. No. 40,378

Telephone No. (650) 225-1994



09157

PATENT TRADEMARK OFFICE

| FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1775R1D1 | Serial No. To Be Assigned | |
|---|-----------------|---|-------------------|------------------------------|------------------------------|-------------|
| | | | | Applicant Baughman et al. | | |
| | | | | Filing Date 20 Jun 2003 | | |
| U.S. PATENT DOCUMENTS | | | | | | |
| Examiner Initials | Document Number | Date | Name | Class | Subclass | Filing Date |
| * 1 | 4,676,980 | 30.06.87 | Segal et al. | | | |
| * 2 | 4,753,894 | 28.06.88 | Frankel et al. | | | |
| * 3 | 4,816,567 | 28.03.89 | Cabilly et al. | | | |
| * 4 | 4,935,341 | 19.06.90 | Bargmann et al. | | | |
| * 5 | 4,943,533 | 24.07.90 | Mendelsohn et al. | | | |
| * 6 | 4,968,603 | 06.11.90 | Slamon et al. | | | |
| * 7 | 4,975,278 | 04.12.90 | Senter et al. | | | |
| * 8 | 5,169,774 | 08.12.92 | Frankel et al. | | | |
| * 9 | 5,183,884 | 02.02.93 | Kraus et al. | | | |
| * 10 | 5,288,477 | 22.02.94 | Bacus, S. | | | |
| * 11 | 5,359,046 | 25.10.94 | Capon et al. | | | |
| * 12 | 5,367,060 | 22.11.94 | Vandlen et al. | | | |
| * 13 | 5,401,638 | 28.03.95 | Carney et al. | | | |
| * 14 | 5,464,751 | 07.11.95 | Greene et al. | | | |
| * 15 | 5,480,968 | 02.01.96 | Kraus et al. | | | |
| * 16 | 5,578,482 | 26.11.96 | Lippman et al. | | | |
| * 17 | 5,604,107 | 18.02.97 | Carney et al. | | | |
| * 18 | 5,641,869 | 24.06.97 | Vandlen et al. | | | |
| * 19 | 5,663,144 | 02.09.97 | Greene et al. | | | |
| * 20 | 5,677,171 | 14.10.97 | Hudziak et al. | | | |
| * 21 | 5,705,157 | 06.01.98 | Greene, M. L. | | | |
| * 22 | 5,720,937 | 24.02.98 | Hudziak et al. | | | |
| * 23 | 5,720,954 | 24.02.98 | Hudziak et al. | | | |
| * 24 | 5,725,856 | 10.03.98 | Hudziak et al. | | | |
| * 25 | 5,726,023 | 10.03.98 | Cheever et al. | | | |
| * 26 | 5,728,687 | 17.03.98 | Bissery, M. | | | |
| * 27 | 5,747,261 | 05.05.98 | King et al. | | | |
| * 28 | 5,770,195 | 23.06.98 | Hudziak et al. | | | |
| * 29 | 5,772,997 | 30.06.98 | Hudziak et al. | | | |
| * 30 | 5,776,427 | 07.07.98 | Thorpe et al. | | | |
| * 31 | 5,783,186 | 21.07.98 | Arakawa et al. | | | |
| * 32 | 5,801,005 | 01.09.98 | Cheever et al. | | | |
| * 33 | 5,821,337 | 13.10.98 | Carter et al. | | | |
| * 34 | 5,824,311 | 20.10.98 | Greene et al. | | | |
| * 35 | 5,834,229 | 10.11.98 | Vandlen et al. | | | |
| * 36 | 5,837,243 | 17.11.98 | Deo et al. | | | |
| Examiner | | | | Date Considered | | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | |

| | | |
|---|-------------------------------------|-------------------------------------|
| FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | Atty Docket No. P1775R1D1 | Serial No. To Be Assigned |
| Applicant Baughman et al. | | |
| Filing Date 20 Jun 2003 | | Group To Be Assigned |

U.S. PATENT DOCUMENTS

| Examiner Initials | | Document Number | Date | Name | Class | Subclass | Filing Date |
|----------------------|------|-----------------|----------|-----------------|-------|----------|-------------|
| | * 37 | 5,837,523 | 17.11.98 | Greene et al. | | | |
| | * 38 | 5,840,525 | 24.11.98 | Vandlen et al. | | | |
| | * 39 | 5,846,538 | 08.12.98 | Cheever et al. | | | |
| | * 40 | 5,856,110 | 05.01.99 | Vandlen et al. | | | |
| | * 41 | 5,859,206 | 12.01.99 | Vandlen et al. | | | |
| | * 42 | 5,869,445 | 09.02.99 | Cheever et al. | | | |
| | * 43 | 5,876,712 | 02.03.99 | Cheever et al. | | | |
| | * 44 | 5,877,305 | 02.03.99 | Huston et al. | | | |
| | * 45 | 5,908,835 | 01.06.99 | Bissery, M. | | | |
| | * 46 | 5,910,486 | 08.06.99 | Curriel et al. | | | |
| | * 47 | 5,922,845 | 13.07.99 | Deo et al. | | | |
| | * 48 | 5,939,531 | 17.08.99 | Wels et al. | | | |
| | * 49 | 5,968,511 | 19.10.99 | Akita et al. | | | |
| | * 50 | 5,977,322 | 02.11.99 | Marks et al. | | | |
| | * 51 | 5,985,553 | 16.11.99 | King et al. | | | |
| | * 52 | 6,015,567 | 18.01.00 | Hudziak et al. | | | |
| | * 53 | 6,028,059 | 22.02.00 | Curriel et al. | | | |
| | * 54 | 6,054,297 | 25.04.00 | Carter et al. | | | |
| | * 55 | 6,054,561 | 25.04.00 | Ring, D. B. | | | |
| | * 56 | 6,096,873 | 01.08.00 | Schaefer et al. | | | |
| | * 57 | 6,123,939 | 26.09.00 | Shawver et al. | | | |
| | * 58 | 6,165,464 | 26.12.00 | Hudziak et al. | | | |
| | * 59 | 6,333,348 | 25.12.01 | Vogel et al. | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | | Document Number | Date | Country | Class | Subclass | Translation Yes No | |
|----------------------|------|-----------------|----------|-------------------------------------|-------|----------|-----------------------|--|
| | * 60 | 0,003,089 A1 | 25.07.79 | EPO (ENGLISH ABSTRACT ATTACHED) | | | | |
| | * 61 | 0,599,274 A1 | 01.06.94 | EPO | | | | |
| | * 62 | 616,812 A1 | 28.09.94 | EPO | | | | |
| | * 63 | 711,565 | 26.08.98 | EPO | | | | |
| | * 64 | 2,761,543B2 | 04.06.98 | JAPAN (TRANSLATION ATTACHED) | | | | |
| | * 65 | 2,895,105B2 | 24.05.99 | JAPAN (ENGLISH ABSTRACT AND CLAIMS) | | | | |
| | * 66 | 3-240498 | 25.10.91 | JAPAN (ENGLISH ABSTRACT ATTACHED) | | | | |
| | * 67 | 5-117165 | 14.05.93 | JAPAN (ENGLISH ABSTRACT ATTACHED) | | | | |
| | * 68 | 5-170667 | 09.07.93 | JAPAN (ENGLISH ABSTRACT ATTACHED) | | | | |
| | * 69 | 5-213775 | 24.08.93 | JAPAN (ENGLISH ABSTRACT ATTACHED) | | | | |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1775R1D1 | Serial No. To Be Assigned | | |
|---|-----------------|--|----------|-------------------------------------|------------------------------|----------------------------|--|
| | | | | Applicant Baughman et al. | | | |
| | | | | Filing Date 20 Jun 2003 | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| Examiner Initials | Document Number | Date | Country | Class | Subclass | Translation Yes No | |
| | * 70 | 5-317084 | 03.12.93 | JAPAN (ENGLISH ABSTRACT ATTACHED) | | | |
| | * 71 | 7-59588 | 07.03.95 | JAPAN (ENGLISH ABSTRACT ATTACHED) | | | |
| | * 72 | 95,006,982B2 | 30.01.95 | JAPAN (ENGLISH ABSTRACT AND CLAIMS) | | | |
| | * 73 | WO 00/61185 | 19.10.00 | PCT | | | |
| | * 74 | WO 89/06692 | 27.07.89 | PCT | | | |
| | * 75 | WO 90/14357 | 29.11.90 | PCT | | | |
| | * 76 | WO 91/00360 | 10.01.91 | PCT | | | |
| | * 77 | WO 92/10573 | 25.06.92 | PCT | | | |
| | * 78 | WO 92/20373 | 26.11.92 | PCT | | | |
| | * 79 | WO 92/20798 | 26.11.92 | PCT | | | |
| | * 80 | WO 93/12220 | 24.06.93 | PCT | | | |
| | * 81 | WO 93/21232 | 28.10.93 | PCT | | | |
| | * 82 | WO 93/21319 | 28.10.93 | PCT | | | |
| | * 83 | WO 94/00136 | 06.01.94 | PCT | | | |
| | * 84 | WO 94/04690 | 03.03.94 | PCT | | | |
| | * 85 | WO 94/22478 | 13.10.94 | PCT | | | |
| | * 86 | WO 94/28127 | 08.12.94 | PCT | | | |
| | * 87 | WO 95/16051 | 15.06.95 | PCT | | | |
| | * 88 | WO 95/17507 | 29.06.95 | PCT | | | |
| | * 89 | WO 95/28485 | 26.10.95 | PCT | | | |
| | * 90 | WO 96/18409 | 20.06.96 | PCT | | | |
| | * 91 | WO 96/27011 | 06.09.96 | PCT | | | |
| | * 92 | WO 97/04801 | 13.02.97 | PCT | | | |
| | * 93 | WO 97/20858 | 12.06.97 | PCT | | | |
| | * 94 | WO 97/27848 | 07.08.97 | PCT | | | |
| | * 95 | WO 97/35885 | 02.10.97 | PCT | | | |
| | * 96 | WO 97/38731 | 23.10.97 | PCT | | | |
| | * 97 | WO 98/02541 | 22.01.98 | PCT | | | |
| | * 98 | WO 98/17797 | 30.04.98 | PCT | | | |
| | * 99 | WO 98/45479 | 15.10.98 | PCT | | | |
| | *100 | WO 99/31140 | 24.06.99 | PCT | | | |
| | *101 | WO 99/48527 | 30.09.99 | PCT | | | |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | *102 | Arteaga et al., "p185c-erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <i>Cancer Research</i> 54(14):3758-3765 (Jul 15, 1994) | | | | | |
| | *103 | Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <i>Molecular Carcinogenesis</i> 3(6):350-362 (1990) | | | | | |
| Examiner | | | | Date Considered | | | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

| | | | | | |
|---|--|---|--|------------------------------|------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1775R1D1 | Serial No. To Be Assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Baughman et al. | |
| | | | | Filing Date 20 Jun 2003 | Group To Be Assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| *104 | Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992) | | | | |
| *105 | Baselga and Mendelsohn, "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994) | | | | |
| *106 | Baselga et al., "Anti HER2 Humanized Monoclonal Antibody (MAB) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" <u>Proceedings of ASCO-13th Annual Meeting</u> (Abstract #53), Dallas, TX 13:63 (Mar 1994) | | | | |
| *107 | Baselga et al., "HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic Implications" <u>Oncology</u> (Supplement No. 2) 11(3):43-48 (March 1997) | | | | |
| *108 | Baselga et al., "Monoclonal Antibodies Directed Against Growth Factor Receptors Enhance the Efficacy of Chemotherapeutic Agents." <u>Annals of Oncology</u> (abstract #010) 5(Suppl. 5) (1994) | | | | |
| *109 | Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996) | | | | |
| *110 | Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" <u>Cancer Research</u> 58:2825-2831 (July 1998) | | | | |
| *111 | Carbonell Castellon et al., "Efficacy and safety of 3-weekly Herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a phase II study" <u>Proc Am Soc Clin Oncol</u> (Abstract #73 from the 2002 ASCO Meeting) 21:19a (2002) | | | | |
| *112 | Carbonell et al., "Efficacy and safety of 3-weekly Herceptin monotherapy in women with HER2-positive metastatic breast cancer: preliminary data from a phase II study" (Oral presentation at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002 in Orlando, Florida) | | | | |
| *113 | Carter et al., "Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992) | | | | |
| *114 | Chothia and Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins" <u>J. Mol. Biol</u> 196:901-917 (1987) | | | | |
| *115 | Cobleigh et al., "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease" <u>Journal of Clinical Oncology</u> 17(9):2639-2648 (Sep 1999) | | | | |
| *116 | D'Souza and Taylor-Papadimitriou., "Overexpression of ERBB2 in Human Mammary Epithelial Cells Signals Inhibition of Transcription of the E-Cadherin Gene." <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994) | | | | |
| *117 | De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein" <u>Cancer Research</u> 52:1916-1923 (1992) | | | | |
| *118 | Di Fiore et al., "erbB-2 Is A Potent Oncogene When Overexpressed In NIH/3T3 Cells." <u>Science</u> 237(4811):178-182 (Jul 10, 1987) | | | | |
| *119 | Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (Jul 1985) | | | | |
| *120 | Drebin et al., "Inhibition of Tumor Growth By a Monoclonal Antibody Reactive With an Oncogene-Encoded Tumor Antigen" <u>Proc. Natl. Acad. Sci.</u> 83:9129-9133 (1986) | | | | |
| *121 | Drebin et al., "Monoclonal Antibodies Reactive With Distinct Domains of the neu Oncogene-Encoded p185 Molecule Exert Synergistic Anti-Tumor Effects In Vivo" <u>Oncogene</u> 2:273-277 (1988) | | | | |
| *122 | Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" <u>Oncogene</u> 2(4):387-394 (1988) | | | | |
| *123 | Fendly, B.M. et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990) | | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|--|---|--|------------------------------|------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1775R1D1 | Serial No. To Be Assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Baughman et al. | |
| | | | | Filing Date 20 Jun 2003 | Group To Be Assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| *124 | Fleiss, JL <u>Statistical Methods for Rates and Proportions</u> , 2nd edition, New York, NY:Wiley pps. 13-17 (1981) | | | | |
| *125 | Gelmon et al., "Pharmacokinetics and safety of Herceptin when administered every 3 weeks to women with metastatic breast cancer" (Oral presentation at the 37th Annual Meeting of the American Society of Clinical Oncology, May 12-15, 2001 in San Francisco, CA) | | | | |
| *126 | Gemzar (gemcitabine HCL), "Product Information - PDR" (2000) | | | | |
| *127 | Goldenberg, M., "Trastuzumab, a Recombinant DNA-Derived Humanized Monoclonal Antibody, a Novel Agent for the Treatment of Metastatic Breast Cancer" <u>Clinical Therapeutics</u> 21(2):309-318 (1999) | | | | |
| *128 | Green et al., "Preclinical Evaluation of WR-151327: An Orally Active Chemotherapy Protector" <u>Cancer Research</u> 54(3):738-741 (Feb 1, 1994) | | | | |
| *129 | Guy et al., "Expression of the neu Protooncogene in the Mammary Epithelium of Transgenic Mice Induces Metastatic Disease." <u>Proc. Natl. Acad. Sci. USA</u> 89(22):10578-10582 (Nov 15, 1992) | | | | |
| *130 | Hancock et al., "A Monoclonal Antibody Against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum Against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (Sep 1, 1991) | | | | |
| *131 | Harris et al., "A population pharmacokinetic (PK) model for Herceptin (H) and implications for clinical dosing" (Oral presentation at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002 in Orlando, Florida) | | | | |
| *132 | Harris et al., "A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing" <u>Proc Am Soc Clin Oncol</u> (Abstract #488) 21:123a (2002) | | | | |
| *133 | Harwerth et al., "Monoclonal Antibodies Against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 25, 1992) | | | | |
| *134 | Hudziak et al., "Increased Expression of the Putative Growth Factor Receptor p185 ^{HER2} Causes Transformation and Tumorigenesis of NIH 3T3 Cells." <u>Proc. Natl. Acad. Sci. USA</u> 84(20):7159-7163 (Oct 1987) | | | | |
| *135 | Hudziak et al., "p185 ^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3):1165-1172 (Mar 1989) | | | | |
| *136 | Hynes and Stern., "The Biology of erbB-2/neu/HER-2 and Its Role in Cancer." <u>Biochimica et Biophysica Acta</u> 1198(2-3):165-184 (Dec 30, 1994) | | | | |
| *137 | Ilgen et al., "Characterization of anti-HER/2 antibodies which inhibit the growth of breast tumor cells in vitro" <u>Proceedings of the American Association for Cancer Research</u> (abstract #3209) 37:470 (Mar 1996) | | | | |
| *138 | Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse." <u>Nature</u> . 321:522-525 (May 29, 1986) | | | | |
| *139 | Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992) | | | | |
| *140 | Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990) | | | | |
| *141 | Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <u>Molecular & Cellular Biology</u> 11(2):979-986 (Feb 1991) | | | | |
| *142 | Lewis et al., "Differential Responses of Human Tumor Cell Lines to Anti-p185 ^{HER2} Monoclonal Antibodies." <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993) | | | | |
| *143 | Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996) | | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|--|---|--|------------------------------|------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1775R1D1 | Serial No. To Be Assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Baughman et al. | |
| | | | | Filing Date 20 Jun 2003 | |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| *144 | Leyland-Jones et al., "Pharmacokinetics of Herceptin administered with paclitaxel every three weeks" <u>Breast Cancer Res Treat</u> (abstract only) 64:124 (2000) | | | | |
| *145 | Maier et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991) | | | | |
| *146 | Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984) | | | | |
| *147 | Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14 (January 1989) | | | | |
| *148 | McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <u>Cancer</u> 65(1):88-92 (Jan 1, 1990) | | | | |
| *149 | McKenzie et al., "Generation and Characterization of Monoclonal Antibodies Specific for the Human neu Oncogene Product, p185" <u>Oncogene</u> 4:543-548 (1989) | | | | |
| *150 | Mendelsohn et al., "Receptor Blockade and Chemotherapy: A New Approach to Combination Cancer Therapy." <u>Annals of Oncology</u> (abstract #040) 7(Suppl. 1):22 (1996) | | | | |
| *151 | Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185neu" <u>Methods in Enzymology</u> 198:277-290 (1991) | | | | |
| *152 | Nakamura, G.R. et al., "Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1" <u>Journal of Virology</u> 67(10):6179-6191 (Oct 1993) | | | | |
| *153 | Norton, L., "Evolving Concepts in the Systemic Drug Therapy of Breast Cancer." <u>Seminars in Oncology</u> 24(4 Suppl 10):S10-3-S10-10 (Aug 1997) | | | | |
| *154 | Pegram et al., "Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers" <u>Oncogene</u> 18:2241-2251 (1999) | | | | |
| *155 | Pegram et al., "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment" <u>Journal of Clin Oncol</u> 16(8):2659-2671 (Aug 1998) | | | | |
| *156 | Pegram et al., "Phase II Study of Receptor-Enhanced Chemosensitivity Using Recombinant Humanized Anti-p185HER2/neu Monoclonal Antibody Plus Cisplatin in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment" <u>Journal of Clinical Oncology</u> 16(8):2659-2671 (1998) | | | | |
| *157 | Pietras et al., "Antibody to HER-2/neu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells" <u>Oncogene</u> 9:1829-1838 (1994) | | | | |
| *158 | Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993) | | | | |
| *159 | Raefsky et al., "Phase II Trial of Docetaxel and Herceptin as First- or Second-Line Chemotherapy for Women with Metastatic Breast Cancer Whose Tumors Overexpress HER2" <u>Proceedings of ASCO (Abstract #523)</u> 18:137a (1999) | | | | |
| *160 | Ravdin and Chamness, "The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review" <u>Gene</u> 159(1):19-27 (Jun 14, 1995) | | | | |
| *161 | Renz, M.E. et al., "Structural requirements for adhesion of soluble recombinant murine vascular cell adhesion molecule-1 to $\alpha 4\beta 1$ " <u>Journal of Cell Biology</u> 125(6):1395-1406 (Jun 1994) | | | | |
| *162 | Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988) | | | | |
| *163 | Rodeck et al., "Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors" <u>J. Cellular Biochem.</u> 35(4):315-320 (1987) | | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|--|---|--|------------------------------|------------------------------|
| FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1775R1D1 | Serial No. To Be Assigned |
| | | | | Applicant Baughman et al. | |
| | | | | Filing Date 20 Jun 2003 | Group To Be Assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| *164 | Sarup et al., "Characterization of an Anti-Pl85HER2 Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991) | | | | |
| *165 | Schlom, J., "Monoclonal Antibodies: They're More and Less Than You Think" <u>Molecular Foundations of Oncology</u> , Broder, S. ed., Baltimore, MD:Williams & Wilkins, Chapter 6, pps. 95-134 (1991) | | | | |
| *166 | Scott et al., "p185HER2 Signal Transduction in Breast Cancer Cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991) | | | | |
| *167 | Seifert et al., "Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity" <u>Annals of Pharmacotherapy</u> 28(9):1063-1072 (Sep 1994) | | | | |
| *168 | Semba et al., "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma" <u>Proc. Natl. Acad. Sci. USA</u> 82:6497-6501 (1985) | | | | |
| *169 | Shawver et al., "Ligand-Like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994) | | | | |
| *170 | Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991) | | | | |
| *171 | Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" <u>The Journal of Immunology</u> 151(4):2296-2308 (Aug 1993) | | | | |
| *172 | Singal and Iliskovic, "Doxorubicin-induced cardiomyopathy" <u>New England J. of Medicine</u> 339(13):900-905 (Sep 24, 1998) | | | | |
| *173 | Singal et al., "Combination therapy with probucol prevents adriamycin-induced cardiomyopathy" <u>Journal of Molecular & Cellular Cardiology</u> 27(4):1055-1063 (Apr 1995) | | | | |
| *174 | Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987) | | | | |
| *175 | Slamon et al., "Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989) | | | | |
| *176 | Slamon et al., "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2" <u>New England J. of Medicine</u> 344(11):783-792 (Mar 15, 2001) | | | | |
| *177 | Sliwkowski et al., "A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer" <u>Proceedings of the American Association for Cancer Research</u> (abstract only) 37:625-626 (Mar 1996) | | | | |
| *178 | Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994) | | | | |
| *179 | Stancovski et al., "Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth" <u>Proc. Natl. Acad. Sci. USA</u> 88(19):8691-8695 (Oct 1, 1991) | | | | |
| *180 | Stevenson et al., "A Chimeric Antibody With Dual Fc Regions (bisFabFc) Prepared by Manipulations at the IgG Hinge." <u>Anti-Cancer Drug Design.</u> 3(4):219-230 (1989) | | | | |
| *181 | Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986) | | | | |
| *182 | Tagliabue et al., "Selection of Monoclonal Antibodies Which Induce Internalization and Phosphorylation of p185HER2 and Growth Inhibition of Cells With HER2/NEU Gene Amplification" <u>International Journal of Cancer</u> 47(6):933-937 (Apr 1, 1991) | | | | |
| *183 | Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988) | | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

